Daewha Sees Promise In Herbal-Derived Alzheimer’s Candidate
This article was originally published in PharmAsia News
Executive Summary
In a rare move, South Korea's Daehwa Pharm is progressing the development of a herbal-derived therapy for Alzheimer's disease, a sector where many pharma firms have been conducting R&D but have faced challenges and failures.
You may also be interested in...
Alzheimer’s Drugs Take Baby Steps Toward Brighter Future
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.